Table 2.
Clinical trials of the use of CAR T cells for treatment of leukaemia and/or lymphoma
| Trial no. | Status | Phase | Treatment | Pre-conditioning | Diagnosis | Sponsor |
|---|---|---|---|---|---|---|
| NCT00709033 | Recruiting | I | CD19 CAR, EBV T cells | No | NHL, CLL | BCM |
| NCT00586391 | Recruiting | I | CD19 CAR 1st vs. 2nd | No | NHL, CLL | BCM |
| NCT00608270 | Recruiting | I | CD19 CAR 1st vs. 2nd 28 | No | Relapsed or refractory NHL, CLL | BCM |
| NCT00840853 | Recruiting | I/II | CD19 CAR, CMV, EBV and Ad trispecific T cells | No | ALL, CLL, NHL pre or post-HSCT | BCM |
| NCT01087294 | Recruiting | I | CD19 CAR, allo-T cells | No | B cell malignancy relapsed post-HSCT | NCI |
| NCT00924326 | Recruiting | I/II | CD19 CAR + IL-2 | Yes | B cell malignancy | NCI |
| NCT01593696 | Recruiting | I | CD19 CAR | No | Paediatric B cell malignancy | NCI |
| NCT01430390 | Recruiting | I | CD19 CAR, alloEBV T cells | No | ALL post-HSCT | MSKCC |
| NCT01044069 | Recruiting | I | CD19 CAR 2nd 28 vs. 4-1BB | No | ALL | MSKCC |
| NCT01029366 | Recruiting | I | CD19 CAR 1st vs. 2nd 4-1BB | No | B cell malignancy | U-Penn |
| NCT00891215 | Recruiting | I | CD19 CAR 1st vs. 2nd 4-1BB | Yes | B cell malignancy | U-Penn |
| NCT00968760 | Recruiting | I | CD19 CAR ± IL-2 | No | B cell malignancy post-HSCT | MDACC |
| NCT01497184 | Recruiting | I | CD19 CAR | No | B cell malignancy post-alloHSCT | MDACC |
| NCT01318317 | Recruiting | I/II | CD19 CAR, CM T cells | No | B cell malignancy post-HSCT | CHMC |
| NCT01475058 | Recruiting | I/II | CD19 CAR, CMV + EBV bispecific, CM T cells | No | B cell malignancy post-HSCT | FHCRC |
| NCT01195480 | Recruiting | I/II | CD19 CAR 1st, EBV T cells + EBV cell vaccine | No | B cell malignancy (paediatric) post-alloHSCT | UCL |
| NCT01316146 | Recruiting | I | CD30 CAR 2nd | No | CD30+ NHL, HL | BCM |
| NCT01192464 | Recruiting | I | CD30 CAR, EBV T cells | No | CD30+ NHL, HL | BCM |
| NCT00881920 | Recruiting | I | Kappa light chain CAR 2nd | No | Kappa+ CLL, lymphoma or MM | BCM |
| NCT00621452 | Ongoing but not recruiting | I | CD20 CAR 3rd and IL-2 | Yes | B cell malignancy | FHCRC |
Trials registered at clinicaltrials.gov as of 15 July 2012.
CAR, chimeric antigen receptor; EBV, Epstein Barr virus; CMV, cytomegalovirus; Ad, adenovirus; 1st, first generation; 2nd, second generation; 3rd, third generation; 28, CD28 domain; HSCT, haematopoietic stem cell transplantation; CM, central memory; NHL, non-Hodgkin's lymphoma; HL, Hodgkin's lymphoma; CLL, chronic lymphocytic leukaemia; MM, multiple myeloma; ALL, acute lymphoblastic leukaemia; BCM, Baylor College of Medicine; NCI, National Cancer Institute; MSKCC, Memorial Sloan-Kettering Cancer Center; U-Penn, University of Pennsylvania; MDACC, MD Anderson Cancer Center; CHMC, City of Hope Medical Center; FHCRC, Fred Hutchinson Cancer Research Center; UCL, University College London.